Literature DB >> 10825607

Local and systemic immune responses to combined vibrio cholerae CVD103-HgR and salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization.

H Kollaritsch1, S J Cryz, A B Lang, C Herzog, J U Que, G Wiedermann.   

Abstract

The local and systemic antibody responses elicited following concomitant primary immunization and reimmunization with the live oral attenuated Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a vaccine strains were determined in healthy adult volunteers. A more pronounced serum vibriocidal antibody response was generated after primary immunization compared to reimmunization 2.5 or 3.5 yr later. The seroconversion rate (> or =4-fold rise over baseline) was 81% subsequent to primary immunization versus 57% (p=0.018) and 65% (p=0.639) upon reimmunization at 2.5 and 3.5 yr, respectively. A similar trend was observed for serum anti-S. typhi lipopolysaccharide (LPS) antibodies. After primary immunization, 48% of subjects manifested a significant rise in coproantibody levels to V. cholerae LPS while 60% did so for cholera toxin (CT). Upon reimmunization, the response rate for LPS ranged from 38% at 2.5 yr to 56% at 3.5 yr (p>0.05), while that for CT varied from 31% (p=0. 007) to 50% (p=0.541) at 2.5 and 3.5 yr, respectively. The anti-S. typhi IgA coproantibody response rate was 70% subsequent to primary immunization versus 47% at 2.5 yr (p=0.021) and 63% at 3.5 yr (p=0. 77).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825607     DOI: 10.1016/s0264-410x(00)00101-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

2.  Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.

Authors:  Rezwanul Wahid; Marcela F Pasetti; Milton Maciel; Jakub K Simon; Carol O Tacket; Myron M Levine; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2010-12-10       Impact factor: 3.969

3.  Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans.

Authors:  Rezwanul Wahid; Raphael Simon; Shah J Zafar; Myron M Levine; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

4.  Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.

Authors:  Rezwanul Wahid; Shah J Zafar; Monica A McArthur; Marcela F Pasetti; Myron M Levine; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

Review 5.  Cyanobacterial lipopolysaccharides and human health - a review.

Authors:  Ian Stewart; Philip J Schluter; Glen R Shaw
Journal:  Environ Health       Date:  2006-03-24       Impact factor: 5.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.